At Coral Drugs, we specialize in delivering cGMP-grade, backward-integrated APIs tailored for global respiratory needs. Our vertically integrated approach ensures consistency, regulatory compliance, and therapeutic reliability, dose after dose.

Our key inhalation APIs include:

• Budesonide
• Ciclesonide
• Fluticasone (Furoate & Propionate)
• Mometasone Furoate (Anhydrous & Monohydrate)

These APIs are essential for the treatment of asthma, COPD, and other respiratory conditions. And at Coral Drugs, we manufacture them with a deep focus on precision and particle size engineering.

One of our core offerings, Fluticasone Propionate, is produced using our in-house micronization technology to achieve aerodynamic particle sizes (1 to 5 microns), high batch uniformity, and consistent lung delivery.

Why does particle size matter? Because it directly impacts deep lung deposition, anti-inflammatory effectiveness, and therapeutic outcomes.

We also offer Azelastine Hydrochloride for targeted nasal relief, with precise control over micronized particle size and impurities, ensuring compliance with global regulatory standards.

With end-to-end integration, cGMP compliance, and a focus on scalability and quality, Coral Drugs is a trusted partner to respiratory health brands across the globe.

Follow our journey and latest innovations on LinkedIn 

Let’s build better respiratory solutions together.

‍